Addex Therapeutics Ltd. (ADXN) is a biopharmaceutical company specializing in the discovery and development of allosteric modulators for neurological disorders. Allosteric modulators are a type of drug that can modify the function of proteins in the body to treat diseases. This approach offers the potential for more targeted therapy with fewer side effects. The company is incorporated in Switzerland with headquarters in Geneva.
Founded in 2007, Addex has a rich history of leveraging its propriety discovery platform to progress a diverse pipeline of allosteric modulators. The company has evolved its scientific focus, concentrating particularly on neurological disorders. Addex’s research has produced therapeutic candidates for various indications, including Parkinson's disease, epilepsy, and addiction.
To put it in perspective, ADXN’s most advanced product candidate is dipraglurant (an oral small molecule allosteric modulator), which targets an orphan indication of Parkinson's disease. The drug has successfully progressed through a phase IIa clinical trial. Another lead molecule, ADX71149, is being developed in collaboration with Janssen Pharmaceuticals, Inc, for the treatment of epilepsy.
Addex uses a cutting-edge approach called allosteric modulation in the development of its therapeutic candidates. Allosteric modulation allows for the fine-tuning of neurotransmitter activity, thus it potentially offers improved therapeutic strategies compared to traditional approaches. The company aims to develop these allosteric modulators not only for neurological disorders but also for more common indications, such as anxiety and depression.
Addex has received numerous awards and grants for its groundbreaking research in allosteric modulation. The company collaborates with academic institutions, biotechnology companies, and pharmaceutical companies to advance its research and development activities. Despite facing significant risk and uncertainty common in the biotechnology sector, Addex remains committed to the potential of allosteric modulators and their promise for a new generation of safer, more effective medicines.
In terms of investment, Addex is recognized as an emerging player in the global biopharmaceutical sector. The company is listed on the Swiss stock exchange (ADXN) and its financial position, business strategy, leadership and scientific innovations, and drug pipeline make it an attractive candidate for investors interested in the biotech sector.
In summary, Addex Therapeutics Ltd. is a forward-thinking biopharmaceutical company that has taken a leading role in the field of allosteric modulation. Its ambition is to redefine the way we treat neurological disorders and potentially transform the drug development paradigm. Despite inevitable industry risks, Addex has distinguished itself as a promising player in the highly competitive pharmaceutical industry.